biosimilars Europe Archives -

AbbVie looks set to lose several billion dollars in revenue from Humira, as its soon to expire European

AbbVie braces for impact of Humira biosimilars in Europe

https://pharmaphorum.com/news/abbvie-braces-for-impact-of-humira-biosimilars-in-europe/

Market Access/ News/ News

Fourth Humira biosimilar set for EU approval

Dominic Tyer AbbVie, adalimumab, biosimilars, biosimilars Europe, CHMP, Humira, Novartis, Sandoz 0 Comment

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s

Fourth Humira biosimilar set for EU approval

https://pharmaphorum.com/news/humira-biosimilar-eu-sandoz-chmp/

Market Access/ News/ News

EC to update IP rules to benefit generic exports

Linda Banks biosimilar, biosimilars Europe, EC, EU, European Commission, European pharma, generics, pharma IP, Pharma regulation 0 Comment

The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe’s pharma companies tap into fast-growing global markets.

EC to update IP rules to benefit generic exports

https://pharmaphorum.com/news/ec-update-ip-rules-generic-exports/

Articles/ Healthcare/ Pharma Market Access/ UK & Europe/ Views and analysis

3 Questions on biosimilars in Europe: Adrian van den Hoven

Andrew McConaghie biosimilars, biosimilars Europe, cancer biosimilars, Medicines for Europe 0 Comment

Adrian van den Hoven of Medicines for Europe addresses three big questions facing the biosmilars sector in Europe in 2018.

3 Questions on biosimilars in Europe: Adrian van den Hoven

https://pharmaphorum.com/views-and-analysis/biosimilars-3-questions-adrian-van-den-hoven-medicines-europe/

Trending

biosimilars Europe

Login